Chengdu Olymvax Biopharmaceuticals (SHSE:688319) ROCE %: 11.38% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688319 Chengdu Olymvax Biopharmaceuticals Inc SHSE:688319
73 GF Score
Price ¥27.01
GF Value ¥23.13
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Chengdu Olymvax Biopharmaceuticals ROCE %?

Chengdu Olymvax Biopharmaceuticals SHSE:688319 +0.33% 73 ROCE % is 11.38% as of Mar. 2026. GuruFocus rates SHSE:688319 with a GF Score™ of 73/100 and a GF Value™ of ¥23.13 (Modestly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Chengdu Olymvax Biopharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 11.38%.

Chengdu Olymvax Biopharmaceuticals  (SHSE:688319) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Chengdu Olymvax Biopharmaceuticals ROCE % Related Terms

Chengdu Olymvax Biopharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Chengdu Olymvax Biopharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chengdu Olymvax Biopharmaceuticals ROCE % Chart

Chengdu Olymvax Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.05 5.25 2.18 3.12 3.73

Chengdu Olymvax Biopharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.09 8.13 13.73 -6.17 11.38
SHSE:688319
73GF Score
Chengdu Olymvax Biopharmaceuticals Inc SHSE:688319
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chengdu Olymvax Biopharmaceuticals ROCE % Calculation

Chengdu Olymvax Biopharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=46.537/( ( (1807.043 - 595.594) + (2023.07 - 737.073) )/ 2 )
=46.537/( (1211.449+1285.997)/ 2 )
=46.537/1248.723
=3.73 %

Chengdu Olymvax Biopharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=146.172/( ( (2023.07 - 737.073) + (2019.912 - 737.061) )/ 2 )
=146.172/( ( 1285.997 + 1282.851 )/ 2 )
=146.172/1284.424
=11.38 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 11.38% mean?
Chengdu Olymvax Biopharmaceuticals (SHSE:688319) has a ROCE % of 11.38% as of Mar. 2026.
Is Chengdu Olymvax Biopharmaceuticals' ROCE % too high?
Chengdu Olymvax Biopharmaceuticals' current ROCE % is 11.38%. Overall, Chengdu Olymvax Biopharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Olymvax Biopharmaceuticals' ROCE % compare to VRTX and REGN?
Chengdu Olymvax Biopharmaceuticals' ROCE % of 11.38% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Chengdu Olymvax Biopharmaceuticals's current ROCE % is 11.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Olymvax Biopharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals (SHSE:688319) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥23.13, compared to a current price of ¥27.01 — trading 16.8% above its estimated fair value. The current ROCE % is 11.38%. Chengdu Olymvax Biopharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Chengdu Olymvax Biopharmaceuticals (SHSE:688319), the current ROCE % is 11.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Overvalued in 2026?

Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals stock appears to be overvalued. The current stock price of ¥27.01 is trading 16.8% above its estimated GF Value™ of ¥23.13. GuruFocus considers Chengdu Olymvax Biopharmaceuticals to be Modestly Overvalued.

Key valuation signals for SHSE:688319:

  • ROCE %: 11.38%
  • GF Value™: ¥23.13 vs. price of ¥27.01 (16.8% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the SHSE:688319 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengdu Olymvax Biopharmaceuticals Business Description

Address 99 Tianxin Road, High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
73GF Score

Get the complete analysis for SHSE:688319

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥27.01
Price
¥23.13
GF Value